Superworth

Quest Diagnostics price to free cash flow DGX

Market value divided by free cash flow over the last twelve months, since 2010.

Today, Nov 3, 2026
20.0×
10-year median
16.1×
Against its 10-year history
93rd
percentile: 0 is its lowest day, 100 its highest
10-year range
8.0× to 26.8×
Peer median
34.3×

Quest Diagnostics' price to free cash flow is 20.0× as of Nov 3, 2026.

That is above its ten-year median of 16.1×, higher than on 93% of days in the last ten years.

Over that time it ranged from 8.0× in Jul 2021 to 26.8× in Jan 2024.

The median for 10 diagnostics and research stocks of a similar size is 34.3×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far20.1×13.9×20.2×
202514.1×14.1×21.4×
202416.7×15.7×26.8×
202326.0×11.1×26.0×
202212.2×8.6×12.2×
202111.3×8.0×12.6×
202011.6×11.6×21.5×
201917.7×12.3×17.8×
201812.2×12.2×17.8×
201715.6×14.6×18.7×
201616.4×14.4×19.7×
201517.5×15.2×18.8×
201417.8×12.2×20.5×
201313.0×8.8×15.2×
20129.4×9.3×13.4×
201112.9×9.5×13.1×
20109.7×7.9×12.9×

Against its peers

Companies in Medical - Diagnostics & Research nearest Quest Diagnostics' size, closest first, today.

CompanyPrice to free cash flow
DGXQuest Diagnostics20.0×
LHLabcorp25.0×
MTDMettler-Toledo International39.6×
ILMNIllumina38.4×
MEDPMedpace25.6×
IQVIQVIA19.4×
WATWaters117×
RVTYRevvity30.3×
AAgilent Technologies39.1×
IDXXIDEXX Laboratories41.5×
BIOBio-Rad Laboratories27.7×
Peer median34.3×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Quest Diagnostics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.